Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar.
| Product Name |
Sitagliptin Hydrochloride Monohydrate |
| CAS Number |
862156-92-1 |
| Therapeutic Class |
Antidiabetic |
| Dosage Form |
Oral Tablets |
| Availability |
Under Development |
| Regulatory Status |
|